Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling

Marine Fidelle; Isabelle Lebhar; Laurence Zitvogel; Guido Guido Kroemer

doi:10.1080/2162402x.2023.2224679

Abstract

1 min read

In a recent paper in Nature, Park et al. propose a mechanism through which intestinal dysbiosis compromises the efficacy of immunotherapy targeting the PD-L1/PD−1 interaction. Dysbiosis may upregulate a pair of checkpoint molecules, i.e. PD-L2 interacting with RGMb. Antibodies targeting PD-L2/RGMb can restore responses to PD−1 blockade in the context of dysbiosis.

Related publications

Article2018

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Joy Hsu, Jonathan J. Hodgins, Malvika Marathe, Chris J. Nicolai, Marie‐Claude Bourgeois‐Daigneault, Troy N. Trevino, Camillia S. Azimi, Amit Scheer, Haley E. Randolph, Thornton W. Thompson, Lily Zhang, Alexandre Iannello, Nikhita Mathur, Karen Jardine, Georgia Kirn, John C. Bell, Michael W. McBurney, David H Raulet, Michele Ardolino

Article2024

Multi‐Functional AIE Phototheranostic Agent Enhancing <i>α</i>PD‐L1 Response for Oral Squamous Cell Carcinoma Immunotherapy

Yuewen Yu, Zihui Ni, Xu Yanbin, Le Zhang, Yu‐Cheng Liu, Fanrui Zeng, Min Zhang, Laikui Liu, Guangxue Feng, Ben Zhong Tang

Article2021

Microbiota-associated immunotherapy resistance caused by deficient PD-L2 - RGMb signaling

Abstract

Discussion(0)

Related publications

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

Multi‐Functional AIE Phototheranostic Agent Enhancing <i>α</i>PD‐L1 Response for Oral Squamous Cell Carcinoma Immunotherapy

Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?

562 Bile acids circumvent gut dysbiosis-induced resistance to anti-PD-1

PD-L1 <sup>+</sup> macrophages suppress T cell-mediated anticancer immunity